| The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology BB Oude Munnink, N Worp, DF Nieuwenhuijse, RS Sikkema, ... Nature medicine 27 (9), 1518-1524, 2021 | 241 | 2021 |
| GPCRmd uncovers the dynamics of the 3D-GPCRome I Rodríguez-Espigares, M Torrens-Fontanals, JKS Tiemann, ... Nature Methods 17 (8), 777-787, 2020 | 142 | 2020 |
| Resolving chemical modifications to a single amino acid within a peptide using a biological nanopore L Restrepo-Pérez, G Huang, PR Bohländer, N Worp, R Eelkema, ... Acs Nano 13 (12), 13668-13676, 2019 | 89 | 2019 |
| An early warning system for emerging SARS-CoV-2 variants L Subissi, A von Gottberg, L Thukral, N Worp, BB Oude Munnink, ... Nature medicine 28 (6), 1110-1115, 2022 | 77 | 2022 |
| Mobilisation and analyses of publicly available SARS-CoV-2 data for pandemic responses N Rahman, C O'cathail, A Zyoud, A Sokolov, B Oude Munnink, B Grüning, ... Microbial genomics 10 (2), 001188, 2024 | 10 | 2024 |
| An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution L Subissi, JR Otieno, N Worp, H Attar Cohen, BB Oude Munnink, ... Nature medicine, 1-4, 2024 | 6 | 2024 |
| Clinical and Virological Outcome of Monoclonal Antibody Therapies Across Severe Acute Respiratory Syndrome Coronavirus 2 Variants in 245 Immunocompromised Patients: A … S Huygens, C GeurtsvanKessel, A Gharbharan, S Bogers, N Worp, ... Clinical Infectious Diseases, ciae026, 2024 | 6 | 2024 |
| Highly divergent SARS-CoV-2 alpha variant in chronically infected immunocompromised person BBO Munnink, RHT Nijhuis, N Worp, M Boter, B Weller, BE Verstrepen, ... Emerging Infectious Diseases 28 (9), 1920, 2022 | 5 | 2022 |
| Towards the development of a SARS-CoV-2 variant risk assessment tool: expert consultation on the assessment of scientific evidence on emerging variants N Worp, L Subissi, MD Perkins, MD Van Kerkhove, A Agrawal, M Chand, ... The Lancet Microbe 4 (10), e830-e836, 2023 | 3 | 2023 |
| Microcalorimetry: A Novel Application to Measure In Vitro Phage Susceptibility of Staphylococcus aureus in Human Serum MM Molendijk, MVT Phan, LGM Bode, N Strepis, DK Prasad, N Worp, ... Viruses 15 (1), 14, 2022 | 3 | 2022 |
| Correction to resolving chemical modifications to a single amino acid within a peptide using a biological nanopore L Restrepo-Pérez, G Huang, PR Bohländer, N Worp, R Eelkema, ... Acs Nano 14 (4), 5148, 2020 | 3 | 2020 |
| Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study S Huygens, C GeurtsvanKessel, A Gharbharan, S Bogers, N Worp, ... Clinical Infectious Diseases 78 (6), 1514-1521, 2024 | 1 | 2024 |
| Mutations in the SARS-CoV-2 genome: the emergence of variants and the impact on vaccines N Worp, MPG Koopmans, RAM Fouchier, OM BB Nederlands Tijdschrift Voor Geneeskunde 165, D6496-D6496, 2021 | | 2021 |
| Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. OM BB, N Worp, DF Nieuwenhuijse, RS Sikkema, B Haagmans, ... Nature Medicine 27 (11), 2048-2048, 2021 | | 2021 |
Marion Koopmanshttps://ncoh.nlEmail verificata su erasmusmc.nl
